Chapter 17. The Optimal use of Infliximab in Crohn's Disease

  1. Derek P. Jewell,
  2. Neil J. Mortensen,
  3. A. Hillary Steinhart,
  4. John H. Pemberton and
  5. Bryan F. Warren
  1. Geert D'Haens

Published Online: 14 JAN 2008

DOI: 10.1002/9780470753170.ch17

Challenges in Inflammatory Bowel Disease, Second Edition

Challenges in Inflammatory Bowel Disease, Second Edition

How to Cite

D'Haens, G. (2006) The Optimal use of Infliximab in Crohn's Disease, in Challenges in Inflammatory Bowel Disease, Second Edition (eds D. P. Jewell, N. J. Mortensen, A. H. Steinhart, J. H. Pemberton and B. F. Warren), Blackwell Publishing Ltd, Malden, Massachusetts, USA. doi: 10.1002/9780470753170.ch17

Publication History

  1. Published Online: 14 JAN 2008
  2. Published Print: 1 JAN 2006

ISBN Information

Print ISBN: 9781405122344

Online ISBN: 9780470753170

SEARCH

Keywords:

  • Crohn's disease;
  • inflammatory process;
  • antibody;
  • apoptosis;
  • inflammatory cells

Summary

This chapter contains section titled:

  • Introduction

  • Use of infliximab for active refractory Crohn's disease

  • Use of infliximab for fistulising Crohn's disease

  • How safe is infliximab?

  • Conclusion